LPA and atherosclerosis: Although outcome studies of therapies dedicated to specific lowering of Lp(a) are ongoing (Assessing the impact of Lipoprotein(a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD [Lp(a) HORIZON]; NCT04023552), the exact mechanisms underlying the increased ASCVD-risk mediated by Lp(a) remain a matter of debate (3).